ReviewClinical, cosmetic and investigational dermatology2025
Prevention and Management of Complications With a Hyaluronic Acid-Calcium Hydroxyapatite Hybrid Injectable.
Review in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global Recommendations for Facial Rejuvenation Using a Hyaluronic Acid and Calcium Hydroxyapatite Hybrid Injectable.Journal of cosmetic dermatology · 2026Guideline
- Expert Panel Guidelines for Hybrid CaHA-CMC/CPM-HA Fillers in the Mexican Population.Journal of cosmetic dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A ready-to-use hyaluronic acid-calcium hydroxyapatite (HA-CaHA) hybrid injectable has a dual mode of action for soft-tissue augmentation. Although previous studies have reported a favorable safety profile for HA-CaHA, there is a need for guidelines and recommendations based on real-world clinical experience for the management of complications associated with HA-CaHA. Purpose: This publication provides guidelines and recommendations for the prevention and management of HA-CaHA-related complications. A case study example, treatment algorithms, and injection techniques are included to illustrate the management of complications. Materials and Methods: On January 25, 2023, 13 European physicians were invited to an advisory board meeting to discuss strategies for optimizing patient care, minimizing adverse events (AEs), and identifying data gaps for the prevention and management of complications with HA-CaHA. Results: The management of a subset of AEs, including skin discoloration and edema, was discussed. Small group workshops also shared management algorithms for late noninflammatory adverse reactions, late inflammatory adverse reactions, localized vascular complications, and retinal vascular complications. Best practices for optimal injection techniques were discussed, and injection-technique protocols were developed for treatment sites. Treatment strategies for HA-CaHA-related complications are considered similar to treatment of those resulting from single-agent fillers, and knowledge of anatomy, aseptic technique, correct injection techniques, and appropriate posttreatment care is emphasized. Conclusion: These recommendations on the management of HA-CaHA-related complications may serve as a reference for the broad range of clinicians using HA-CaHA hybrid injectable for different indications and can help optimize patient outcomes and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.